Aimed Bio Inc.
PublicAimed Bio Inc. is now publicly traded
The data on this page reflects Aimed Bio Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Private Equity
Jun 2, 2025
Total Funding Raised
$66.45M
Company Overview
Aimed Bio Inc. has raised $66.45M. It was founded in 2018.
Aimed Bio Inc. is a biotechnology company that develops antibody-based therapeutics, including antibody-drug conjugates (ADCs), for refractory brain diseases and cancer.
AI Layer
Non-AI
Aimed Bio Inc. Comparables
Compare Aimed Bio Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GeneQuantum Healthcare | 86% | |
| Duality Biotherapeutics Inc | 85% | |
| Trioar | 84% |
For institutional investors. Book with your work email.
Aimed Bio Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Jun 2, 2025 | ||||
| Series B | Jul 31, 2024 | ||||
| Strategic | Sep 13, 2023 |
For institutional investors. Book with your work email.
Aimed Bio Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series B, Private Equity |
| Samsung Life Public Welfare Foundation | Private Equity |
| DS Asset Management | Series B, Private Equity |
| Mirae Asset Securities | Private Equity |
| Mint Venture Partners | Series B |
Aimed Bio Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.